Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $33.00 Average PT from Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have earned a consensus recommendation of “Hold” from the seven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $27.60.

PCRX has been the subject of a number of recent analyst reports. Truist Financial reduced their price objective on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a research report on Monday. Wall Street Zen upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pacira BioSciences in a research report on Wednesday, October 8th.

Pacira BioSciences Trading Up 0.4%

Shares of PCRX stock opened at $23.88 on Friday. Pacira BioSciences has a 52-week low of $16.00 and a 52-week high of $27.64. The company has a 50-day simple moving average of $23.88 and a two-hundred day simple moving average of $24.32. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.91 and a current ratio of 2.38. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -8.59 and a beta of 0.36.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, November 6th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. The firm had revenue of $179.52 million for the quarter, compared to the consensus estimate of $182.86 million. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The company’s revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.79 EPS. Pacira BioSciences has set its FY 2025 guidance at EPS. Research analysts anticipate that Pacira BioSciences will post 2.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its stake in shares of Pacira BioSciences by 17.8% in the second quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company’s stock valued at $84,000 after buying an additional 531 shares during the period. US Bancorp DE grew its stake in shares of Pacira BioSciences by 31.0% during the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock worth $56,000 after acquiring an additional 537 shares during the period. Hantz Financial Services Inc. increased its holdings in Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after acquiring an additional 721 shares during the last quarter. Inspire Investing LLC raised its stake in Pacira BioSciences by 5.1% in the 3rd quarter. Inspire Investing LLC now owns 17,402 shares of the company’s stock valued at $448,000 after acquiring an additional 846 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Pacira BioSciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after acquiring an additional 1,165 shares during the period. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.